Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Trop Med Hyg. 2012 Dec;87(6):1046-52. doi: 10.4269/ajtmh.2012.11-0761. Epub 2012 Oct 22.

Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome.

Author information

  • 1Department of Medicine, Køge Hospital, Lykkebækvej 1, Køge, Denmark. engsbro@live.dk

Abstract

The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.

PMID:
23091195
[PubMed - indexed for MEDLINE]
PMCID:
PMC3516073
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk